Format

Send to

Choose Destination
Nat Rev Cancer. 2011 Jul 14;11(8):541-57. doi: 10.1038/nrc3087.

Advances in sarcoma genomics and new therapeutic targets.

Author information

1
Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

Erratum in

  • Nat Rev Cancer. 2011;11(9):685.

Abstract

Increasingly, human mesenchymal malignancies are being classified by the abnormalities that drive their pathogenesis. Although many of these aberrations are highly prevalent within particular sarcoma subtypes, few are currently targeted therapeutically. Indeed, most subtypes of sarcoma are still treated with traditional therapeutic modalities, and in many cases sarcomas are resistant to adjuvant therapies. In this Review, we discuss the core molecular determinants of sarcomagenesis and emphasize the emerging genomic and functional genetic approaches that, coupled with novel therapeutic strategies, have the potential to transform the care of patients with sarcoma.

PMID:
21753790
PMCID:
PMC3361898
DOI:
10.1038/nrc3087
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center